Insider Buying: Palisade Bio (NASDAQ:PALI) Director Buys 20,000 Shares

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera bought 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The stock was bought at an average cost of $1.99 per share, for a total transaction of $39,800.00. Following the completion of the transaction, the director directly owned 436,904 shares of the company’s stock, valued at approximately $869,438.96. The trade was a 4.80% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 9th, Robert Jr. Baltera purchased 25,000 shares of Palisade Bio stock. The shares were bought at an average cost of $1.96 per share, with a total value of $49,000.00.
• On Tuesday, July 7th, Robert Jr. Baltera purchased 30,000 shares of Palisade Bio stock. The shares were bought at an average cost of $2.03 per share, with a total value of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were bought at an average cost of $2.05 per share, for a total transaction of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera purchased 10,000 shares of Palisade Bio stock. The stock was bought at an average price of $1.98 per share, for a total transaction of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was bought at an average price of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Price Performance

PALI stock traded down $0.01 during trading on Friday, reaching $1.96. 3,452,719 shares of the stock traded hands, compared to its average volume of 4,120,886. The firm has a market capitalization of $340.22 million, a PE ratio of -1.94 and a beta of 1.50. Palisade Bio, Inc. has a 52-week low of $0.53 and a 52-week high of $2.85. The business’s 50 day moving average price is $1.92 and its 200-day moving average price is $1.92.

Palisade Bio (NASDAQ:PALI) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, equities research analysts predict that Palisade Bio, Inc. will post -0.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PALI shares. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Palisade Bio in a report on Tuesday, June 30th. Oppenheimer set a $7.00 price target on shares of Palisade Bio in a research report on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Finally, Weiss Ratings raised Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.83.

Hedge Funds Weigh In On Palisade Bio

Institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers purchased a new position in shares of Palisade Bio during the 4th quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth approximately $26,000. Virtu Financial LLC bought a new stake in shares of Palisade Bio in the fourth quarter worth $28,000. CTC Alternative Strategies Ltd. bought a new stake in shares of Palisade Bio in the first quarter worth $31,000. Finally, Atom Investors LP acquired a new stake in Palisade Bio in the fourth quarter valued at $33,000. 11.79% of the stock is owned by institutional investors and hedge funds.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.